Evidence map›Paper›PMID 30949915›Full record

ArticleBreast cancer (Tokyo, Japan)2019

Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.

Yukie Omori, Sotaro Enatsu, Zhihong Cai, Hiroshi Ishiguro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Quality of life with ribociclibTherapeutic advances in medical oncology · 2023
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yukie OmoriEli Lilly Japan K.K., Medicines Development Unit Japan, Akasaka Garden City 13F, 4-15-1, Akasaka, Minato-ku, Tokyo, 107-0052, Japan. omori_yukie@lilly.com.
Sotaro EnatsuEli Lilly Japan K.K., Medicines Development Unit Japan, 5-1-28, Isogamidori, Chuo-ku, Kobe, Japan.
Zhihong CaiEli Lilly Japan K.K., Medicines Development Unit Japan, Akasaka Garden City 13F, 4-15-1, Akasaka, Minato-ku, Tokyo, 107-0052, Japan.
Hiroshi IshiguroInternational University of Health and Welfare Hospital, Nasushiobara, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to identify factors affecting patients' preferences for postmenopausal hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer treatments, their relative importance, and impact of sociodemographic/clinical characteristics.

methodsJapanese postmenopausal patients with HR+ breast cancer chose between 2 hypothetical treatments for HR+/HER2- advanced breast cancer using an online discrete choice experiment, defined by different levels of 5 attributes: progression-free survival (PFS), incidence of diarrhea (IOD), frequency of loose stools of grade 1-3 severity (FOS), duration of diarrhea (DOD), and route/frequency of administration (RFA). Conditional logit modeling identified relative preferences for each attribute. Subgroup analyses, based on sociodemographic characteristics (age, employment status, age of youngest child, marital status) and clinical characteristics (relapse/metastasis, hormone sensitivity), identified factors affecting preferences.

resultsOf 896 participants screened, 258 eligible participants were included in analyses. Patient preferences, when the potential frequency of diarrhea was grade 2, were (strongest to weakest): PFS, DOD, FOS, IOD, RFA; however, when the potential frequency of diarrhea was grade 3, FOS became most important. Sociodemographic/clinical characteristics tended to affect preferences.

conclusionsJapanese postmenopausal patients with HR+ breast cancer preferred treatments that extend PFS despite potential grade 2 diarrhea. However, when diarrhea severity increased to grade 3, patients were more willing to sacrifice PFS to avoid more frequent diarrhea. Prevention or limitation of diarrhea to grade ≤ 2 is important for maintaining patients' motivation for treatment that can extend PFS. Additionally, patient characteristics (age, family context, therapeutic experience) should be considered during treatment choice.

Indexed as

Patient PreferencePostmenopauseAminopyridinesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesBreast NeoplasmsDiarrheaErb-b2 Receptor Tyrosine KinasesFemaleFulvestrantHumansJapanMiddle AgedProgression-Free SurvivalReceptors, EstrogenabemaciclibAminopyridinesAntineoplastic Agents, HormonalBenzimidazolesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFulvestrantReceptors, EstrogenReceptors, ProgesteroneBreast cancerCyclin-dependent kinase 4Cyclin-dependent kinase 6Patient preference

Identifiers

PMID30949915
PMCPMC6694082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.